Pivot Xavier, Magné Nicolas, Guardiola Emmanuel, Poissonnet Gilles, Dassonville Olivier, Francoual Mireille, Formento Jean-Louis, Bensadoun René-Jean, Demard François, Schneider Maurice, Milano Gérard
Department of Medical Oncology, CHU J. Minjoz, 25030 Besancon Cedex, France.
Oral Oncol. 2005 Mar;41(3):320-7. doi: 10.1016/j.oraloncology.2004.09.011.
The aim of this study was to analyse prognostic factors for disease free interval (DFI) and overall survival (OS) among patients with larynx and hypopharynx cancer requiring a total laryngectomy. Three groups of patients were studied according to the type of treatment they received. Fifty-eight patients had total laryngectomy, 71 patients had organ preservation treatment including induction chemotherapy followed by exclusive radiotherapy, 26 patients received induction chemotherapy followed by salvage total laryngectomy. The studied potential prognostic factors were age, gender, performans status, primary tumor localization, T status, N status, tumor volume and tumoral EGFR level (fmol/mg protein). The multivariate analysis showed that both N status and tumor volume were significant for DFI and OS. EGFR level was significant only for patients treated by induction chemotherapy and exclusive radiotherapy (p = 0.05 and 0.05 for DFI and OS length, respectively). Among this group, patients with tumor EGFR levels lower and higher than 100 fmol/mg protein had 53% versus 22% and 51% versus 18% 5-year of DFI and OS rates, respectively (Log rank test: p = 0.001 and 0.0001). EGFR determination appears to be a powerful prognostic parameter for patients treated by induction chemotherapy followed by exclusive radiotherapy. Laryngectomy seems to erase the prognostic impact of EGFR expression. These results profile the use of EGFR targeting therapy for this category of patients.
本研究的目的是分析需要进行全喉切除术的喉癌和下咽癌患者的无病生存期(DFI)和总生存期(OS)的预后因素。根据患者接受的治疗类型将其分为三组进行研究。58例患者接受了全喉切除术,71例患者接受了器官保留治疗,包括诱导化疗后单纯放疗,26例患者接受诱导化疗后挽救性全喉切除术。研究的潜在预后因素包括年龄、性别、体能状态、原发肿瘤部位、T分期、N分期、肿瘤体积和肿瘤表皮生长因子受体(EGFR)水平(fmol/mg蛋白)。多因素分析显示,N分期和肿瘤体积对DFI和OS均具有显著意义。EGFR水平仅对接受诱导化疗和单纯放疗的患者具有显著意义(DFI和OS时长的p值分别为0.05和0.05)。在该组患者中,肿瘤EGFR水平低于和高于100 fmol/mg蛋白的患者5年DFI率分别为53%和22%,5年OS率分别为51%和18%(对数秩检验:p = 0.001和0.0001)。对于接受诱导化疗后单纯放疗的患者,EGFR检测似乎是一个有力的预后参数。全喉切除术似乎消除了EGFR表达的预后影响。这些结果为这类患者使用EGFR靶向治疗提供了依据。